Switching to pegmolesatide for anemia in people on dialysis
Official title: Pegmolesatide for Anemia Treatment：Investigation Upgrade Therapy in rhuEPO Patients Undergoing Dialysis: A Prospective, Multicenter, Parallel-Group, Controlled, Open-Label Study（PANGU-stepup）
Run by Chinese PLA General Hospital · NCT07045155 · Data updated 2026-11-12
This 24-week test will try whether switching dialysis patients whose anemia isn't at goal from rHuEPO to pegmolesatide alone or combined with roxadustat keeps or raises hemoglobin better than continuing rHuEPO.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 240 (estimated) |
| Sponsor | Chinese PLA General Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | August 1, 2025 |
| Main results expected | December 30, 2027 |
| Study ends | December 30, 2028 |
| Registry record updated | September 12, 2025 |
| Trial ID | NCT07045155 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–80 years on hemodialysis or peritoneal dialysis for ≥3 months, weighing ≥40 kg with BMI ≥18 kg/m², receiving ESAs for ≥4 weeks (equivalent short-acting EPO >6000 IU/week), and with screening and baseline Hb between 70 and <110 g/L and adequate ferritin levels per dialysis modality.
✕Probably not a fit
Patients not on maintenance dialysis, those with Hb below 70 g/L or ≥110 g/L, those with insufficient iron stores, or those needing imminent renal transplant are unlikely to match the study population or obtain benefit from the study interventions.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, multicenter, open-label, randomized 1:1:1 trial enrolling 240 dialysis-dependent CKD patients with renal anemia who have been on rHuEPO for at least 4 weeks and have hemoglobin between 70 and <110 g/L. Participants will be assigned to continue rHuEPO (control), switch to pegmolesatide monotherapy (experimental), or switch to pegmolesatide plus roxadustat (exploratory) and followed for 24 weeks including screening, treatment, and an extension period. The primary outcome compares hemoglobin changes across the three regimens, with safety and tolerability monitored throughout. The trial is open-label and conducted at multiple centers in China, led by the Chinese PLA General Hospital.
Why it matters
Potential benefit: If successful, this approach could provide dialysis patients an alternative ESA option that maintains or improves hemoglobin control, potentially with different dosing or convenience.
How similar studies have gone: Erythropoiesis-stimulating agents and some EPO-mimetic peptides have corrected renal anemia in prior trials, though agents in this class have sometimes shown safety issues, so newer switching strategies are being re-examined.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged ≥18 years and ≤80 years, with no restrictions on gender. 2. Body weight ≥40 kg and body mass index (BMI) ≥18 kg/m². 3. Subjects who have received hemodialysis or peritoneal dialysis for ≥3 months prior to enrollment; 4. Subjects who have been receiving erythropoiesis-stimulating agents (ESAs) for ≥4 weeks prior to randomization, with an average weekly dose \>6000 IU in the last 4 weeks (equivalent dose converted to short-acting EPO \>6000 IU, calculated as the total amount of short-acting EPO used in the last 4 weeks divided by 4); 5. The most recent Hb value during the screening period and the average Hb value between screening and baseline visits must be ≥70 to \<110 g/L; 6. Hemodialysis patients with serum ferritin levels ≥200 μg/L; peritoneal dialysis patients with serum ferritin levels ≥100 μg/L, and the investigator determines that renal transplant is not required during the trial; 7. Understanding the study procedures and voluntarily signing the Informed Consent Form (ICF). Exclusion Criteria: 1. Known to have active malignancy, polycystic kidney disease, hematologic disorders (including congenital and acquired anemias such as thalassemia, Fanconi anemia, pure red cell aplasia, myelodysplastic syndromes, hemolytic anemia, and coagulation disorders), or other causes of anemia (such as gastrointestinal bleeding or hookworm disease); 2. Known to have experienced stroke, transient ischemic attack, myocardial infarction, thromboembolic events (deep vein thrombosis), pulmonary embolism, or other serious cardiopulmonary diseases within the past 6 months; 3. Received anabolic steroid (e.g., androgen) therapy within 12 weeks prior to randomization; 4. Known to have received red blood cell or whole blood transfusion within 12 weeks prior to the study. 5. History of significant infection within 4 weeks before randomization as determined by the investigator. 6. Confirmed blood pressure measurements at rest and in a conscious state using standard measurement methods, with at least three non-consecutive day readings reaching or exceeding systolic blood pressure (SBP) ≥180 mmHg and/or diastolic blood pressure (DBP) ≥110 mmHg within 4 weeks before enrollment, or changes in antihypertensive medication treatment. The primary basis for judgment is clinic-measured blood pressure values, but "white coat hypertension" should be excluded. 7. Known allergy to iron agents or polyethylene glycol. 8. Pregnant or breastfeeding women, women of childbearing age with a positive blood β-HCG test result before the trial, or those planning to become pregnant during the study period. 9. Scheduled for elective surgery during the trial period. 10. Presence of any other factors that the investigator deems unsuitable for participation in this trial.
Where it's running
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Xiangmei Chen — Chinese PLA General Hospital
- Study coordinator: Ping Li, M.D.
- Email: liping.8@163.com
- Phone: +8615810136659
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Italian Registry of Pediatric Dialysis: collecting data from kids on kidney replacement therapy
This registry in Italy tests how collecting epidemiological, clinical, and treatment data from children on dialysis or pre-emptive kidney transplants can help centers share protocols and improve care.
-
3D Ultrasound Support for Hemodialysis Cannulation
This study tests whether the EchoMap device can help safely cannulate an arm fistula during hemodialysis for adults.
-
Creatine and intradialytic exercise in people on hemodialysis
The study tests whether taking creatine and doing in-dialysis exercise can improve body composition and physical function in adults with CKD on maintenance hemodialysis.
-
Laser acupuncture for fatigue in adults on hemodialysis
This trial tests whether low-level laser acupuncture can reduce fatigue and improve quality of life for adults with end-stage kidney disease who are on regular hemodialysis, compared with a sham treatment.
-
Italian cooperative hemoadsorption for relieving uremic symptoms
This registry will follow adults on maintenance hemodialysis to see if adding hemoadsorption to their dialysis helps relieve persistent uremic symptoms.
-
Low-intensity versus standard-intensity continuous dialysis for critically ill adults with acute kidney injury
This will try giving lower-intensity continuous dialysis instead of the usual intensity to adults in intensive care with acute kidney injury to see if kidneys recover just as well with fewer side effects.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.